Compare DexCom, Inc. (DXCM) vs HubSpot Inc (HUBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs HubSpot Inc — how do they compare? DexCom, Inc. trades at $77.66 (market cap $28.06B), while HubSpot Inc trades at $221.95 (market cap $11.02B). The key difference: DexCom, Inc. is far larger — about 2.5× HubSpot Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, HubSpot Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | HUBS | |
|---|---|---|
Market Cap | $28.06B | $11.02B |
Sector | Health | Technology |
52-Week High | $89.53 | $560.90 |
52-Week Low | $54.84 | $170.39 |
Enterprise Value | $27.03B | $9.58B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
HubSpot (HUBS) trades at $209.68, down 3.64% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $268.75. The company reported Q1 2026 EPS of $2.72, beating estimates, and shows strong revenue growth, reaching $3.13B in 2025. Positive sentiment is driven by AI integration and customer expansion, with 80.85% of analysts rating it a Buy.
The outlook for HUBS is positive, supported by robust revenue growth, expanding AI capabilities, and consistent earnings beats. Key risks include high valuation multiples and competitive pressures in the CRM space. Investors should monitor execution on AI monetization and margin improvement for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →
